The information on this website is not intended for diagnosis or treatment. Please consult your physician for health concerns.

+90 850 321 50 00

COVID-19 Vaccine Safety in Children

Pediatric vaccine effectiveness, side effect profile, and recommendations

Written by: Saygı Hospital Health Guide Editorial Board
Last updated:

This content has been compiled by the Saygı Hospital Health Guide Editorial Board and is periodically reviewed by a specialist physician.

References (5)

This content is for informational purposes only and does not constitute medical advice. You can book an appointment at our Internal Medicine department. Book Appointment →

What is COVID-19 Vaccine Safety in Children?

COVID-19 vaccines for children include Pfizer-BioNTech (Comirnaty) and Moderna (Spikevax) mRNA vaccines authorized down to 6 months of age in many regions, with age-appropriate dosing (3 mcg or 10 mcg for children under 12 with Pfizer; 25 mcg for younger children with Moderna). Inactivated, protein subunit (Novavax), and other vaccine platforms are available in different regions. Initial primary series and updated booster doses target current circulating variants.

Safety in children has been extensively characterized through clinical trials, real-world surveillance, and post-authorization studies. Common side effects are mild local reactions (injection site pain, redness, swelling) and systemic reactions (fatigue, headache, myalgia, fever, especially after second dose). Most reactions resolve within 1-2 days. Serious adverse events are rare. Myocarditis (mostly mild, self-limited) occurs at increased rates in adolescent and young adult males (peak risk 16-24 years), particularly after second mRNA dose, with rates of 70-100 per million doses, lower than the rate caused by COVID-19 infection itself.

Effectiveness against severe disease, hospitalization, and MIS-C has been demonstrated even with variants. Efficacy against symptomatic infection wanes over time and varies by variant, supporting periodic boosters. Vaccination has been particularly important for children with chronic medical conditions (immunocompromise, cardiac, pulmonary, metabolic, neurological disorders). Coadministration with other routine pediatric vaccines is supported. Patient and family counseling addresses common concerns including myocarditis, future fertility, long-term safety, and component allergies.

Symptoms

Common reactions: injection site pain, redness, swelling
Fatigue, headache
Myalgia, arthralgia
Low-grade fever
Chills
Lymphadenopathy (axillary)
Mild gastrointestinal symptoms (nausea, vomiting, diarrhea)
Decreased appetite
Irritability in young children
Reactions usually within 24-48 hours
More common after second dose than first
Myocarditis or pericarditis (rare): chest pain, palpitations, dyspnea typically 2-7 days post-dose
Allergic reactions to vaccine components (rare): anaphylaxis to PEG, polysorbate
Stevens-Johnson syndrome (extremely rare)
Thrombosis with thrombocytopenia syndrome (TTS, with adenoviral vector vaccines, not mRNA, very rare)
Bell palsy (rare temporal association)
Vasovagal reactions
Concerns about long-term effects (no significant evidence found)
Concerns about fertility (no evidence of impact)
Concerns about menstrual cycle (transient effects observed)

Risk Factors

Age-specific risk profiles
Adolescent males 16-24 years (myocarditis risk highest)
Pre-existing myocarditis history (relative caution)
Multisystem inflammatory syndrome in children (MIS-C) history
Severe allergy to vaccine component (PEG, polysorbate)
Severe allergic reaction to first dose
Immunocompromise (typically receives additional doses)
Underlying cardiac, pulmonary, metabolic, neurological conditions
Pregnancy in adolescent (vaccination supported)
Recent COVID-19 infection (delay 3 months recommended in some guidelines)
Concurrent acute illness with fever (delay until recovery)
Bleeding disorders (use small needle, prolonged pressure)
Anticoagulation therapy
Family history of myocarditis (no contraindication, individualized counseling)
Variant-specific waning immunity
Time since last dose or infection
Coadministration considerations
Vaccine hesitancy and family concerns
Limited access to vaccine in some regions
Misinformation exposure

When to See a Doctor?

If you experience any of the following symptoms, seek medical attention promptly:

  • Routine COVID-19 vaccination consideration for child
  • Booster dose timing inquiries
  • Concerns about side effects
  • Underlying conditions affecting vaccination
  • Severe local reaction at injection site
  • Persistent fever beyond 48 hours
  • Chest pain, palpitations, or dyspnea after vaccination (urgent)
  • Concerning systemic symptoms
  • Allergy history evaluation
  • Recent COVID-19 infection timing for vaccination
  • Coadministration with other vaccines
  • Specific medical conditions requiring tailored guidance

Treatment Methods

01
Comprehensive history including allergies, prior vaccines, medical conditions
02
Vaccine selection appropriate for age (Pfizer-BioNTech, Moderna based on availability)
03
Updated booster (XBB.1.5 monovalent or current variant-targeted) per current guidelines
04
Age-specific dosing: 3-25 mcg depending on product and age
05
Primary series: 2-3 doses depending on age and product
06
Booster doses recommended periodically based on current guidelines
07
Site preparation and proper injection technique
08
Observation for 15-30 minutes post-vaccination (longer for high-risk allergy)
09
Anaphylaxis preparedness (epinephrine, oxygen, monitoring)
10
Patient and family education on common reactions
11
Symptomatic treatment of mild reactions (acetaminophen, ibuprofen)
12
Rest after vaccination
13
Avoid intense exercise for 1 week post mRNA vaccine (especially adolescents) to reduce myocarditis risk (controversial guidance)
14
Recognition of myocarditis symptoms requiring urgent evaluation
15
Workup for suspected myocarditis: ECG, troponin, BNP, echocardiography, cardiac MRI
16
Treatment of myocarditis: rest, NSAIDs, IVIG in selected cases, hospitalization if symptoms
17
Counseling on infection vs vaccine risk-benefit
18
Evidence sharing addressing common concerns
19
Coadministration with other routine pediatric vaccines supported
20
Documentation in electronic immunization records
21
Public health reporting of serious adverse events
22
Special protocols for immunocompromised children (additional doses)
23
Strategies for vaccine hesitancy: motivational interviewing, reliable sources, family conversations
24
Regional variation in product availability and recommendations
25
Long-term surveillance through V-safe and similar systems
26
Multidisciplinary approach for complex pediatric medical conditions

Which Department to Visit?

You can visit our Enfeksiyon Hastalıkları department for these complaints. Our specialist physicians will create the most suitable treatment plan for you.

Learn About Enfeksiyon Hastalıkları Department

Let us help you

You can make an appointment with our specialists or contact us for your concerns.

Book AppointmentContact Us

Related Health Topics

Other articles from the same department you may want to explore.

Flu (Influenza)

Enfeksiyon Hastalıkları

Influenza is a seasonal contagious respiratory disease caused by influenza viruses; it presents with high fever, muscle pain, and severe fatigue.

COVID-19

Enfeksiyon Hastalıkları

COVID-19 is a contagious disease caused by the SARS-CoV-2 coronavirus with a wide clinical spectrum ranging from asymptomatic to severe pneumonia.

Upper Respiratory Tract Infection

Enfeksiyon Hastalıkları

Upper respiratory tract infections are diseases that include common cold, pharyngitis, sinusitis, and laryngitis, often of viral origin and self-limited.

Urinary Tract Infection

Enfeksiyon Hastalıkları

Urinary tract infections are common bacterial infections most often caused by Escherichia coli, presenting with burning and frequent urination.

Hepatitis A (HAV)

Enfeksiyon Hastalıkları

Hepatitis A is an acute, self-limited liver infection transmitted via the fecal-oral route causing acute hepatitis without chronicity; supportive care suffices in most cases, while vaccination prevents outbreaks and post-exposure prophylaxis within 2 weeks is effective.

Hepatitis B

Enfeksiyon Hastalıkları

Hepatitis B is a contagious infection caused by HBV virus transmitted via blood, sexual intercourse, and mother-to-child, that can become chronic and progress to cirrhosis and liver cancer.

Hepatitis C

Enfeksiyon Hastalıkları

Hepatitis C is a liver disease caused by HCV virus transmitted mainly by blood; the rate of chronicity is high, but cure is possible with new antiviral drugs.

HIV/AIDS Information

Enfeksiyon Hastalıkları

HIV is a virus that targets the immune system; if untreated, it progresses to AIDS. With modern antiretroviral therapy, HIV-positive individuals can lead healthy, long lives.

Health Disclaimer: The information on this page is prepared for general informational purposes only. It does not replace medical diagnosis and treatment. Please consult your physician for your complaints. Saygı Hospital does not accept responsibility for actions taken based on the information on this page.